2021 KSTCVS建议：体外膜肺氧合治疗COVID-19

2021-02-05 国外胸外科相关专家组（统称） J Chest Surg . 2021 Feb 5

自2019年12月首例冠状病毒病（COVID-19）报告以来，尽管经过多因素的努力，确诊病例和死亡人数仍在成倍增加。虽然近10年来，人们做出了各种尝试，以提高体外膜氧合（ECMO）治疗的证据水平，但对

中文标题：

英文标题：

Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019: Expert Recommendations from The Korean Society for Thoracic and Cardiovascular Surgery

发布机构：

国外胸外科相关专家组（统称）

发布日期：

2021-02-05

简要介绍：

自2019年12月首例冠状病毒病（COVID-19）报告以来，尽管经过多因素的努力，确诊病例和死亡人数仍在成倍增加。虽然近10年来，人们做出了各种尝试，以提高体外膜氧合（ECMO）治疗的证据水平，但对于COVID-19患者是否应用ECMO，大多数专家仍然犹豫不决。最近已经发表了一些ECMO管理指南，但它们反映了与韩国医疗体系和韩国现实世界医疗实践的一些重要差异。我们旨在通过回顾已发表的文献，寻找COVID-19患者ECMO疗效的证据，并通过分析韩国COVID-19 ECMO登记数据，提出专家建议。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=983451c0020e7325, title=2021 KSTCVS建议：体外膜肺氧合治疗COVID-19, enTitle=Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019: Expert Recommendations from The Korean Society for Thoracic and Cardiovascular Surgery, guiderFrom=J Chest Surg . 2021 Feb 5, authorId=0, author=, summary=自2019年12月首例冠状病毒病（COVID-19）报告以来，尽管经过多因素的努力，确诊病例和死亡人数仍在成倍增加。虽然近10年来，人们做出了各种尝试，以提高体外膜氧合（ECMO）治疗的证据水平，但对, cover=https://img.medsci.cn/2021330/1617117970117_2020535.jpg, journalId=0, articlesId=null, associationId=1877, associationName=国外胸外科相关专家组（统称）, associationIntro=, copyright=0, guiderPublishedTime=Fri Feb 05 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>自2019年12月首例冠状病毒病（COVID-19）报告以来，尽管经过多因素的努力，确诊病例和死亡人数仍在成倍增加。虽然近10年来，人们做出了各种尝试，以提高体外膜氧合（ECMO）治疗的证据水平，但对于COVID-19患者是否应用ECMO，大多数专家仍然犹豫不决。最近已经发表了一些ECMO管理指南，但它们反映了与韩国医疗体系和韩国现实世界医疗实践的一些重要差异。我们旨在通过回顾已发表的文献，寻找COVID-19患者ECMO疗效的证据，并通过分析韩国COVID-19 ECMO登记数据，提出专家建议。</p>, tagList=[TagDto(tagId=8355, tagName=体外膜肺氧合)], categoryList=[CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=38, categoryName=急重症科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=8355, guiderKeyword=体外膜肺氧合, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11193, appHits=79, showAppHits=0, pcHits=356, showPcHits=11113, likes=0, shares=2, comments=5, approvalStatus=1, publishedTime=Tue Mar 30 23:50:47 CST 2021, publishedTimeString=2021-02-05, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Mar 30 23:26:17 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 10:47:48 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 KSTCVS建议：体外膜肺氧合治疗COVID-19.pdf)])

2021 KSTCVS建议：体外膜肺氧合治疗COVID-19.pdf

下载请点击：

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1051761, encodeId=07691051e611c, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 00:14:11 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976499, encodeId=22d49e649972, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/6f6883dbb0e24f0087875ef21cc0f282/62f7bae59f3e41cbacff5bc8d8f4ba1a.jpg, createdBy=cde45526117, createdName=Linxuezhang, createdTime=Thu Jun 24 12:11:38 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958926, encodeId=b76a95892623, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62505123547, createdName=1463ea10m76暂无昵称, createdTime=Tue Apr 20 23:16:32 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956790, encodeId=1caf956e9043, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeb95477852, createdName=ms3000001338146104, createdTime=Wed Apr 14 08:17:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954230, encodeId=0573954230b1, content=EcM0是救治可逆重症疾病的利器, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a37e5423044, createdName=ms6000000252401279, createdTime=Tue Apr 06 15:55:46 CST 2021, time=2021-04-06, status=1, ipAttribution=)]
2021-09-16 湘雅科教

值得学习

56 0
[GetPortalCommentsPageByObjectIdResponse(id=1051761, encodeId=07691051e611c, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 00:14:11 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976499, encodeId=22d49e649972, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/6f6883dbb0e24f0087875ef21cc0f282/62f7bae59f3e41cbacff5bc8d8f4ba1a.jpg, createdBy=cde45526117, createdName=Linxuezhang, createdTime=Thu Jun 24 12:11:38 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958926, encodeId=b76a95892623, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62505123547, createdName=1463ea10m76暂无昵称, createdTime=Tue Apr 20 23:16:32 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956790, encodeId=1caf956e9043, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeb95477852, createdName=ms3000001338146104, createdTime=Wed Apr 14 08:17:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954230, encodeId=0573954230b1, content=EcM0是救治可逆重症疾病的利器, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a37e5423044, createdName=ms6000000252401279, createdTime=Tue Apr 06 15:55:46 CST 2021, time=2021-04-06, status=1, ipAttribution=)]
2021-06-24 Linxuezhang

学习

63 0
[GetPortalCommentsPageByObjectIdResponse(id=1051761, encodeId=07691051e611c, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 00:14:11 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976499, encodeId=22d49e649972, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/6f6883dbb0e24f0087875ef21cc0f282/62f7bae59f3e41cbacff5bc8d8f4ba1a.jpg, createdBy=cde45526117, createdName=Linxuezhang, createdTime=Thu Jun 24 12:11:38 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958926, encodeId=b76a95892623, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62505123547, createdName=1463ea10m76暂无昵称, createdTime=Tue Apr 20 23:16:32 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956790, encodeId=1caf956e9043, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeb95477852, createdName=ms3000001338146104, createdTime=Wed Apr 14 08:17:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954230, encodeId=0573954230b1, content=EcM0是救治可逆重症疾病的利器, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a37e5423044, createdName=ms6000000252401279, createdTime=Tue Apr 06 15:55:46 CST 2021, time=2021-04-06, status=1, ipAttribution=)]
2021-04-20 1463ea10m76暂无昵称

值得学习

59 0
[GetPortalCommentsPageByObjectIdResponse(id=1051761, encodeId=07691051e611c, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 00:14:11 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976499, encodeId=22d49e649972, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/6f6883dbb0e24f0087875ef21cc0f282/62f7bae59f3e41cbacff5bc8d8f4ba1a.jpg, createdBy=cde45526117, createdName=Linxuezhang, createdTime=Thu Jun 24 12:11:38 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958926, encodeId=b76a95892623, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62505123547, createdName=1463ea10m76暂无昵称, createdTime=Tue Apr 20 23:16:32 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956790, encodeId=1caf956e9043, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeb95477852, createdName=ms3000001338146104, createdTime=Wed Apr 14 08:17:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954230, encodeId=0573954230b1, content=EcM0是救治可逆重症疾病的利器, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a37e5423044, createdName=ms6000000252401279, createdTime=Tue Apr 06 15:55:46 CST 2021, time=2021-04-06, status=1, ipAttribution=)]
2021-04-14 ms3000001338146104

学习

70 0
[GetPortalCommentsPageByObjectIdResponse(id=1051761, encodeId=07691051e611c, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 00:14:11 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976499, encodeId=22d49e649972, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/6f6883dbb0e24f0087875ef21cc0f282/62f7bae59f3e41cbacff5bc8d8f4ba1a.jpg, createdBy=cde45526117, createdName=Linxuezhang, createdTime=Thu Jun 24 12:11:38 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958926, encodeId=b76a95892623, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62505123547, createdName=1463ea10m76暂无昵称, createdTime=Tue Apr 20 23:16:32 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956790, encodeId=1caf956e9043, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eeb95477852, createdName=ms3000001338146104, createdTime=Wed Apr 14 08:17:45 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954230, encodeId=0573954230b1, content=EcM0是救治可逆重症疾病的利器, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a37e5423044, createdName=ms6000000252401279, createdTime=Tue Apr 06 15:55:46 CST 2021, time=2021-04-06, status=1, ipAttribution=)]
2021-04-06 ms6000000252401279

EcM0是救治可逆重症疾病的利器

66 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

呼吸指南

2021 KSTCVS建议：体外膜肺氧合治疗COVID-19

相关指南

拓展阅读

科室

工具

服务